Estudo randomizado: Ruxolitinibe tópico para o tratamento de vitiligo

Neste estudo duplo-cego, randomizado e multicêntrico de Fase 2 com 157 pacientes a medicação levou a melhora na pigmentação cutânea em 45% a 50% dos pacientes.

Fonte:

Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial – The Lancet

Comentário Relacionado no Twitter

NEW—Treatment with ruxolitinib cream was associated with substantial repigmentation of vitiligo lesions up to 52 weeks of treatment, and all doses were well tolerated: finding from a randomised, controlled, phase 2 trial https://t.co/Td5nlsMcYI pic.twitter.com/CHvtspGstQ

— The Lancet (@TheLancet) July 10, 2020